LEGN Legend Biotech Corp

Nasdaq legendbiotech.com


$ 28.19 $ 0.64 (2.32 %)    

Friday, 21-Nov-2025 15:55:06 EST
QQQ $ 590.00 $ 4.40 (0.75 %)
DIA $ 462.48 $ 5.05 (1.1 %)
SPY $ 658.74 $ 6.50 (1 %)
TLT $ 89.49 $ 0.27 (0.3 %)
GLD $ 373.69 $ -0.58 (-0.15 %)
$ 28.17
$ 27.44
$ 28.10 x 165
$ 28.15 x 267
$ 27.41 - $ 28.23
$ 27.34 - $ 45.30
2,054,470
na
5.17B
$ 0.63
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 barclays-maintains-overweight-on-legend-biotech-lowers-price-target-to-90

Barclays analyst Gena Wang maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $94 to ...

 rbc-capital-maintains-outperform-on-legend-biotech-lowers-price-target-to-74

RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and lowers the price target fro...

 legend-biotech-announces-official-opening-of-its-new-rd-facility-in-philadelphia

31,000-square-foot site expands Legend's U.S. R&D footprint and strengthens its position as a global leader in cell the...

 cantor-fitzgerald-maintains-overweight-on-legend-biotech-raises-price-target-to-75

Cantor Fitzgerald analyst Eric Schmidt maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and raises the price target ...

 legend-biotech-q3-adj-eps-005-beats-010-estimate-sales-272330m-miss-272499m-estimate

Legend Biotech (NASDAQ:LEGN) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.10...

 hc-wainwright--co-maintains-buy-on-legend-biotech-lowers-price-target-to-60

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Legend Biotech (NASDAQ:LEGN) with a Buy and lowers the price ta...

 jp-morgan-maintains-overweight-on-legend-biotech-lowers-price-target-to-76

JP Morgan analyst Jessica Fye maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $78 ...

Core News & Articles

Legend Biotech USA Inc. Enters into Component and Product Supply Agreement with Janssen Pharmaceuticals, Inc.On October 6, 2025...

 legend-biotech-is-said-to-explore-second-listing-outside-of-us--bloomberg

https://www.bloomberg.com/news/articles/2025-09-05/legend-biotech-is-said-to-explore-second-listing-outside-of-us

 cantor-fitzgerald-assumes-legend-biotech-at-overweight-announces-price-target-of-66

Cantor Fitzgerald analyst Eric Schmidt assumes Legend Biotech (NASDAQ:LEGN) with a Overweight rating and announces Price Tar...

 jp-morgan-maintains-overweight-on-legend-biotech-raises-price-target-to-78

JP Morgan analyst Jessica Fye maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and raises the price target from $77 ...

 rbc-capital-maintains-outperform-on-legend-biotech-raises-price-target-to-77

RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and raises the price target fro...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION